Overview

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Status:
RECRUITING

Trial end date:
2026-05-07

Target enrollment:

Participant gender:

Summary

All participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen). Serum samples for assessment of immune response will be collected at baseline (visit of first vaccination) and at 2 weeks (week 6), 6 months (week 30), and 1 year after the second (last) vaccination.

Phase:

PHASE2

Details

Lead Sponsor:

Bavarian Nordic

Collaborator:

Coalition for Epidemic Preparedness Innovations

Treatments:

smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic